First-Line Treatment for Advanced Colorectal Cancer

Introduction to First-Line Treatment

The European Society for Medical Oncology recommends FOLFOX (5-fluorouracil/leucovorin/oxaliplatin) as a first-line treatment for advanced colorectal cancer, providing better survival than 5-FU/LV alone and similar efficacy to FOLFIRI (5-FU/LV/irinotecan) but with a different toxicity profile 1, 2

FOLFOX can be combined with targeted agents, such as bevacizumab (anti-VEGF antibody), which improves progression-free survival when added to FOLFOX 1, 2
Cetuximab (anti-EGFR antibody) can be added to FOLFOX in KRAS wild-type patients 1
CAPOX (capecitabine plus oxaliplatin) is an acceptable alternative to standard FOLFOX, with similar activity 1, 2

Treatment should continue until disease progression or unacceptable toxicity, with consideration of treatment interruptions for cumulative toxicity or disease control 1, 2, 4
Maintenance with fluoropyrimidine alone after initial combination therapy prolongs progression-free survival compared to complete treatment break 2

Assess response after 2-3 months of treatment with history and physical examination, CEA level (if initially elevated), and CT scan of involved regions 1, 4, 5
Initially unresectable liver metastases may become resectable after downsizing with FOLFOX, and surgical evaluation should be considered in patients with good response 3, 4, 6
Monitor for peripheral neuropathy (common with oxaliplatin) and consider dose modifications for severe adverse reactions 2, 4

For patients who progress on FOLFOX, an irinotecan-based regimen (FOLFIRI) should be considered as second-line treatment, and for patients who received FOLFIRI first-line, FOLFOX is the recommended second-line option 1, 2